Dexamethasone and prednisone’s pro-apoptotic and anti-proliferative effects are blocked by genetic anomalies and/or mutations occurring in the glucocorticoid receptor NR3C1 in relapsed multiple myeloma patients. This evidence concerns the gene NR3C1 and plasma cell myeloma.